LIGAND PHARMACEUTICALS INC - COM NEW (LGND)

Historical Portfolio Holders from Q1 2014 to Q3 2024

All holders as of September 30, 2024
Q3 2024
Type / Class
Equity / COM NEW
Shares, excl. options Q3 2024
18.1M
Holdings value Q3 2024
$1.81B
Value change Q3 2024
+$73.6M
Grand Portfolio weight change Q3 2024
+0%
Number of holders
237
Number of buys Q3 2024
130
Number of sells Q3 2024
-77
Average buys Q3 2024 %
+0%
Average sells Q3 2024 %
-0.001%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Period Shares, Excl. Options Value, Excl. Options Change Price Investors
2024 Q3 18.1M $1.81B +$73.6M $100.09 238
2024 Q2 17.3M $1.45B +$88M $84.26 230
2024 Q1 16.4M $1.2B +$27.3M $73.10 219
2023 Q4 16.1M $1.15B +$38.5M $71.42 208
2023 Q3 15.6M $938M -$1.77M $59.92 192
2023 Q2 15.6M $1.12B +$43.4M $72.10 201
2023 Q1 14.9M $1.1B +$24.8M $73.56 207
2022 Q4 14.7M $983M -$15.5M $66.80 192
2022 Q3 14.8M $1.28B -$9.22M $86.11 195
2022 Q2 14.9M $1.33B -$60.7M $89.22 184
2022 Q1 15.6M $1.76B -$96.5M $112.49 191
2021 Q4 16.3M $2.51B -$20.7M $154.46 213
2021 Q3 16.4M $2.29B +$72.1M $139.32 205
2021 Q2 15.9M $2.08B +$57.3M $131.19 210
2021 Q1 15.4M $2.35B -$1.01B $152.45 220
2020 Q4 22.8M $2.26B -$7.35M $99.45 232
2020 Q3 22.9M $2.18B +$68.8M $95.32 250
2020 Q2 22.1M $2.47B -$52.1M $111.85 256
2020 Q1 22.9M $1.67B -$13.5M $72.72 254
2019 Q4 22.7M $2.37B -$63.6M $104.29 257
2019 Q3 23.3M $2.32B -$162M $99.54 270
2019 Q2 24.9M $2.84B -$64.5M $114.15 301
2019 Q1 25.9M $3.25B -$121M $125.71 324
2018 Q4 26.8M $3.63B +$252M $135.70 355
2018 Q3 24.2M $6.64B -$320M $274.49 376
2018 Q2 25.6M $5.3B +$188M $207.17 342
2018 Q1 24.7M $4.07B +$62.3M $165.16 319
2017 Q4 24.7M $3.38B -$24.7M $136.93 297
2017 Q3 24.6M $3.35B -$96.4M $136.15 286
2017 Q2 24.5M $2.97B +$87M $121.40 258
2017 Q1 24.6M $2.6B +$242M $105.84 249
2016 Q4 24.8M $2.52B +$333K $101.61 266
2016 Q3 24.3M $2.48B +$61.3M $102.06 255
2016 Q2 24.7M $2.94B -$22.6M $119.27 260
2016 Q1 24.7M $2.64B +$160M $107.09 247
2015 Q4 23.2M $2.51B +$43M $108.42 230
2015 Q3 22.8M $1.95B -$18.5M $85.65 202
2015 Q2 21.6M $2.18B -$68.2M $100.90 214
2015 Q1 22.1M $1.71B +$80.9M $77.11 184
2014 Q4 21.7M $1.15B -$4.36M $53.21 180
2014 Q3 21.7M $1.02B +$40.5M $46.99 173
2014 Q2 20.5M $1.27B -$5.27M $62.29 191
2014 Q1 20.8M $1.4B +$30.1M $67.26 182